Adis Journals
Browse
Summary slide.png (83.22 kB)

Long-Term Cost-Effectiveness Analyses of Empagliflozin versus Oral Semaglutide, in Addition to Metformin, For the Treatment of Type 2 Diabetes in the UK

Download (83.22 kB)
media
posted on 2020-07-21, 08:58 authored by Mafalda Ramos, Michael H. Cummings, Anastasia Ustyugova, Syed I. Raza, Shamika U. de Silva, Mark Lamotte

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2020.

History

Usage metrics

    Diabetes Therapy

    Categories

    Keywords

    Costs and cost analysisCost-effectivenessDiabetes mellitusEmpagliflozinGLP-1 receptor agonistsOral semaglutideSGLT-2 inhibitorsTreatment intensificationUnited Kingdom

    Licence

    CC BY-NC 4.0

    Exports